Strategies for hepatitis C therapeutic intervention: Now and next

Current Opinion in Pharmacology

Volumn 4, Issue 5, 2004, Pages 465-470

  Tan, Seng Lai ^a   He, Yupeng ^b   Huang, Ying ^a,c   Gale Jr , Michael ^d  

^a ELI LILLY AND COMPANY   (United States)

^b ABBOTT LABORATORIES   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN ALPHA INTERFERON; ALPHA INTERFERON; ALPHA2B INTERFERON; AMANTADINE; AZATHIOPRINE; BENZIMIDAZOLE DERIVATIVE; BETA INTERFERON; BETA1 INTERFERON; CILUPREVIR; CONSENSUS INTERFERON; GAMMA1B INTERFERON; GUANOSINE TRIPHOSPHATE; HEPATITIS C VACCINE; IMMUNOMODULATING AGENT; INTERFERON REGULATORY FACTOR 3; ISATORIBINE; JTK 003; LEVOVIRIN; MERIMEPODIB; PEGINTERFERON; PEGINTERFERON ALPHA2A; PROTEINASE INHIBITOR; RIBAMIDINE; RIBAVIRIN; RIMANTADINE; SMALL INTERFERING RNA; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VX 950; ANTIVIRUS AGENT; HEPATITIS VACCINE; INTERFERON;

ANTIVIRAL ACTIVITY; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; DRUG BINDING SITE; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INDIVIDUALITY; INFLUENZA VIRUS A; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS REPLICATION; ANIMAL; DRUG COMBINATION; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; PROTEIN PROCESSING; REVIEW;

ANIMALS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; PROTEIN ISOPRENYLATION; RIBAVIRIN; VIRAL HEPATITIS VACCINES; VIRUS REPLICATION;

EID: 16644390861     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2004.07.003     Document Type: Review

References (47)

1. J.G. McHutchison Understanding hepatitis C Am J Manag Care 10 Suppl 2004 S21-S29
2. B.L. Pearlman Hepatitis C infection: A clinical review South Med J 97 2004 364-373
3. R. Bartenschlager A. Kaul S. Sparacio Replication of the hepatitis C virus in cell culture Antiviral Res 60 2003 91-102
4. S.L. Tan A. Pause Y. Shi N. Sonenberg Hepatitis C therapeutics: Current status and emerging strategies Nat Rev Drug Discov 1 2002 867-881
5. J.Y. Lau R.C. Tam T.J. Liang Z. Hong Mechanism of action of ribavirin in the combination treatment of chronic HCV infection Hepatology 35 2002 1002-1009
6. J.M. Pawlotsky H. Dahari A.U. Neumann C. Hezode G. Germanidis I. Lonjon L. Castera D. Dhumeaux Antiviral action of ribavirin in chronic hepatitis C Gastroenterology 126 2004 703-714
7. V.E. Buckwold Implications of finding synergic in vitro drug-drug interactions between interferon-alpha and ribavirin for the treatment of hepatitis C virus J Antimicrob Chemother 53 2004 413-414
8. K.C. Young K.L. Lindsay K.J. Lee W.C. Liu J.W. He S.L. Milstein M.M. Lai Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy Hepatology 38 2003 869-878
9. J. Larkin L. Jin M. Farmen D. Venable Y. Huang S.L. Tan J.I. Glass Synergistic antiviral activity of human interferon combinations in the hepatitis C virus replicon system J Interferon Cytokine Res 23 2003 247-257
10. A. Mangia G. Leandro B. Helbling E.L. Renner M. Tabone L. Sidoli S. Caronia G.R. Foster S. Zeuzem T. Berg et al. Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials J Hepatol 40 2004 478-483
11. Biotech Business press release, 04/01/2004. [URL: http://www.scicloneinternational.com/]
12. J.R. Stangl K.L. Carroll M. Illichmann R. Striker Effect of antimetabolite immunosuppressants on Flaviviridae, including hepatitis C virus Transplantation 77 2004 562-567
13. E. Foy K. Li C. Wang R. Sumpter Jr M. Ikeda S.M. Lemon M. Gale Jr Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease Science 300 2003 1145-1148
14. D. Lamarre P.C. Anderson M. Bailey P. Beaulieu G. Bolger P. Bonneau M. Bos D.R. Cameron M. Cartier M.G. Cordingley et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus Nature 426 2003 186-189
15. M. Llinas-Brunet M.D. Bailey G. Bolger C. Brochu A.M. Faucher J.M. Ferland M. Garneau E. Ghiro V. Gorys C. Grand-Maitre et al. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061 J Med Chem 47 2004 1605-1608
16. L. Lu T.J. Pilot-Matias K.D. Stewart J.T. Randolph R. Pithawalla W. He P.P. Huang L.L. Klein H. Mo A. Molla Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro Antimicrob Agents Chemother 48 2004 2260-2266
17. D. Thibeault C. Bousquet R. Gingras L. Lagace R. Maurice P.W. White D. Lamarre Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061 J Virol 78 2004 7352-7359
18. G.C. Sen Viruses and interferons Annu Rev Microbiol 55 2001 255-281
19. C. Lin K. Lin Y.P. Luong B.G. Rao Y.Y. Wei D.L. Brennan J.R. Fulghum H.M. Hsiao S. Ma J.P. Maxwell et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms J Biol Chem 279 2004 17508-17514
20. Y. Yip F. Victor J. Lamar R. Johnson Q.M. Wang D. Barket J. Glass L. Jin L. Liu D. Venable et al. Discovery of a novel bicycloproline P2 bearing peptidyl alpha-ketoamide LY514962 as HCV protease inhibitor Bioorg Med Chem Lett 14 2004 251-256
21. F. Victor J. Lamar N. Snyder Y. Yip D. Guo N. Yumibe R.B. Johnson Q.M. Wang J.I. Glass S.H. Chen P1 and P3 optimization of novel bicycloproline P2 bearing tetrapeptidyl alpha-ketoamide based HCV protease inhibitors Bioorg Med Chem Lett 14 2004 257-261
22. J. Lamar F. Victor N. Snyder R.B. Johnson Q.M. Wang J.I. Glass S.H. Chen Novel P4 truncated tripeptidyl alpha-ketoamides as HCV protease inhibitors Bioorg Med Chem Lett 14 2004 263-266
23. D.F. Wyss A. Arasappan M.M. Senior Y.S. Wang B.M. Beyer F.G. Njoroge M.A. McCoy Non-peptidic small-molecule inhibitors of the single-chain hepatitis C virus NS3 protease/NS4A cofactor complex discovered by structure-based NMR screening J Med Chem 47 2004 2486-2498
24. V.R. Hegde H. Pu M. Patel P.R. Das N. Butkiewicz G. Arreaza V.P. Gullo T.M. Chan Two antiviral compounds from the plant Stylogne cauliflora as inhibitors of HCV NS3 protease Bioorg Med Chem Lett 13 2003 2925-2958
25. D. Dhanak K.J. Duffy V.K. Johnston J. Lin-Goerke M. Darcy A.N. Shaw B. Gu C. Silverman A.T. Gates M.R. Nonnemacher et al. Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase J Biol Chem 277 2002 38322-38327
26. V.K. Johnston D. Maley R.C. Gagnon C.W. Grassmann S.E. Behrens R.T. Sarisky Kinetic profile of a heterocyclic HCV replicon RNA synthesis inhibitor Biochem Biophys Res Commun 311 2003 672-677
27. T.T. Nguyen A.T. Gates L.L. Gutshall V.K. Johnston B. Gu K.J. Duffy R.T. Sarisky Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor Antimicrob Agents Chemother 47 2003 3525-3530
28. L. Tomei S. Altamura L. Bartholomew A. Biroccio A. Ceccacci L. Pacini F. Narjes N. Gennari M. Bisbocci I. Incitti et al. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase J Virol 77 2003 13225-13231
29. A.K. Raney R.K. Hamatake Z. Hong HEP DART 2003: Frontiers in drug development for viral hepatitis Expert Opin Investig Drugs 13 2004 289-293
30. A.B. Eldrup C.R. Allerson C.F. Bennett S. Bera B. Bhat N. Bhat M.R. Bosserman J. Brooks C. Burlein S.S. Carroll et al. Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase J Med Chem 47 2004 2283-2295
31. G. Migliaccio J.E. Tomassini S.S. Carroll L. Tomei S. Altamura B. Bhat L. Bartholomew M.R. Bosserman A. Ceccacci L.F. Colwell et al. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro J Biol Chem 278 2003 49164-49170
32. L. Hollecker H. Choo Y. Chong C.K. Chu S. Lostia T.R. McBrayer L.J. Stuyver J.C. Mason J. Du S. Rachakonda et al. Synthesis of beta-enantiomers of N4-hydroxy-3′-deoxypyrimidine nucleosides and their evaluation against bovine viral diarrhoea virus and hepatitis C virus in cell culture Antivir Chem Chemother 15 2004 43-55
33. G.W. Witherell ISIS-14803 (Isis Pharmaceuticals) Curr Opin Investig Drugs 2 2001 1523-1529
34. T. Hugle A. Cerny Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C Rev Med Virol 13 2003 361-371
35. J. Kronke R. Kittler F. Buchholz M.P. Windisch T. Pietschmann R. Bartenschlager M. Frese Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs J Virol 78 2004 3436-3446
36. T. Yokota N. Sakamoto N. Enomoto Y. Tanabe M. Miyagishi S. Maekawa L. Yi M. Kurosaki K. Taira M. Watanabe H. Mizusawa Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs EMBO Rep 4 2003 602-608
37. J.A. Wilson S. Jayasena A. Khvorova S. Sabatinos I.G. Rodrigue-Gervais S. Arya F. Sarangi M. Harris-Brandts S. Beaulieu C.D. Richardson RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells Proc Natl Acad Sci U S A 100 2003 2783-2788
38. S.B. Kapadia A. Brideau-Andersen Chisari FV Interference of hepatitis C virus RNA replication by short interfering RNAs Proc Natl Acad Sci U S A 100 2003 2014-2018
39. G. Randall A. Grakoui C.M. Rice Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs Proc Natl Acad Sci U S A 100 2003 235-240
40. A.P. McCaffrey L. Meuse T.T. Pham D.S. Conklin G.J. Hannon M.A. Kay RNA interference in adult mice Nature 418 2002 38-39
41. S.E. Bassett B. Guerra K. Brasky E. Miskovsky M. Houghton G.R. Klimpel R.E. Lanford Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection Hepatology 33 2001 1479-1487
42. R.E. Lanford B. Guerra D. Chavez C. Bigger K.M. Brasky X.H. Wang S.C. Ray D.L. Thomas Cross-genotype immunity to hepatitis C virus J Virol 78 2004 1575-1581
43. Reuters press Release 03/25/2004. [URL: http://www.innogenetics.be/].
44. Virus Weekly Press release 03/23/2004. [URL: http://www.nabi.com/].
45. J.M. Lund L. Alexopoulou A. Sato M. Karow N.C. Adams N.W. Gale A. Iwasaki R.A. Flavell Recognition of single-stranded RNA viruses by Toll-like receptor 7 Proc Natl Acad Sci U S A 101 2004 5598-5603
46. J. Ye C. Wang R. Sumpter Jr M.S. Brown J.L. Goldstein M. Gale Jr Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation Proc Natl Acad Sci U S A 100 2003 15865-15870
47. wsRxHepatitis via NewsEdge Corporation, 31 May 2004. [URL: http://www.NewsRx.com/]